Newsroom
latest news from ose
and across our portfolio
Featured News
All News
Portfolio NewsBarinthus BiotherapeuticsBarinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial ResultsPortfolio NewsBarinthus BiotherapeuticsBarinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November ConferencesPortfolio NewsDiffBlueDiffblue Secures $6.3 Million in New Funding Amidst 3x Growth PeriodPortfolio NewsCaristo DiagnosticsCaristo Diagnostics Wins Digital Health Award for CaRi-Heart® Cardiac Risk Prediction TechnologyPortfolio NewsFractileFractile on song as ARIA awards £5m to AI chip design pioneerPortfolio NewsNucleome TherapeuticsNucleome Therapeutics announces a strategic collaboration with Johnson & Johnson to map genetic associations linked to autoimmune diseasePortfolio NewsBeacon TherapeuticsBeacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis PigmentosaPortfolio NewsFluorokFluoRok secures £700k grant to develop the UK supply of a crucial component of Lithium-ion batteriesPortfolio NewsBarinthus BiotherapeuticsBarinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate CancerPortfolio NewsOxford NanoimagingONI and Massive Photonics Announce a Successful Collaboration Bringing DNA-PAINT Technology to the NanoimagerPortfolio NewsGenomicsGenomics plc Announces David Thornton as PresidentPortfolio NewsBarinthus BiotherapeuticsBarinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac DiseasePortfolio NewsFluorokFluoRok raises £7.7m ($9.8m) to transform the safety and sustainability of fluorochemical productionPortfolio NewsOxford IonicsOxford Ionics sets new world record in qubit readoutPortfolio NewsTheolyticsTheolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UKPortfolio NewsPepGenPepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & DevelopmentPortfolio NewsPepGenPepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & DevelopmentPortfolio NewsMoA TechnologyMoa Announces International Field Trial Success at the ACS Autumn Conference in DenverPortfolio NewsOxford IonicsOxford Ionics kicks off international expansion with new US officePortfolio NewsSpyBiotechSpyBiotech Appoints Dr. Prakash Bhuyan as Chief Medical OfficerPortfolio NewsPepGenPepGen Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsPortfolio NewsBarinthus BiotherapeuticsBarinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial ResultsPortfolio NewsPepGenPepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular DystrophyPortfolio NewsIota SciencesiotaSciences raises equity financing round to drive further business expansion for its automated single-cell biology handling technologiesPortfolio NewsFractileFractile raises $15 million to develop new AI ChipPortfolio NewsBeacon TherapeuticsBeacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial OfficerPortfolio NewsSpyBiotechSpyBiotech Announces the Completion of Enrollment in Phase I Trial of SPYVLO1 Targeting Human Cytomegalovirus (HCMV)Portfolio NewsNeu.Health DigitalPioneering Parkinson’s Care: The First NHS Outcomes using the Neu Health PlatformPortfolio NewsMixergyDaikin partner with Mixergy to offer unparalleled benefits for social housing retrofit and new buildOSE NewsOxford Semantic TechnologiesOxford Spinout Oxford Semantic Technologies acquired by Samsung ElectronicsPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Mark Bodmer as Chief Executive OfficerPortfolio NewsOxford IonicsOxford Ionics breaks global quantum performance recordsPortfolio NewsMoA TechnologyMoa harvests global deal for new herbicideOSE NewsTimes Commentary: Science innovation must be at the heart of government actionPortfolio NewsBeacon TherapeuticsBeacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene TherapiesPortfolio NewsNatcapNatcap Secures $10 Million to Bring Nature into Business Decision-MakingPortfolio NewsSitryxSitryx announces leadership transitionPortfolio NewsSitryxSitryx announces leadership transitionPortfolio NewsPQShieldPQShield raises $37m in Series B funding to deliver the widespread commercial adoption of quantum resistant cryptographyOSE NewsOxford Science Enterprises Appoints Professor Dame Fiona Murray and Professor Sir Peter Donnelly as Non-Executive DirectorsPortfolio NewsBarinthus BiotherapeuticsBarinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus InfectionsPortfolio NewsBeacon TherapeuticsBeacon Therapeutics Treats First Patient in VISTA Registrational Trial for AGTC-501Portfolio NewsAmber Therapeutics Closes $100 Million Series A - one of the largest European MedTech raisesPortfolio NewsOrbit DiscoverySecarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated Targeted Antisense Oligonucleotide TherapeuticsPortfolio NewsGrey Wolf TherapeuticsGrey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences Team, to Accelerate and Expand First-of-its-Kind Antigen Modulation TechnologyPortfolio NewsSpyBiotechSpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of OxfordOSE NewsOSE announces groundbreaking new partnership with The Crown Estate and Pioneer GroupPortfolio NewsOxford EndovascularOxford Endovascular – raises £8m to tackle brain aneurysmsPortfolio NewsScenic Biotech enters into Research Collaboration with Bristol Myers SquibbPortfolio NewsGenomicsGenomics and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial designPortfolio NewsEvox TherapeuticsEvox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive OfficerPortfolio NewsCaristo DiagnosticsNewsweek Selects Caristo Diagnostics as One of World's Best Digital Health CompaniesPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading expertsOSE NewsOxford Science Enterprises welcomes Kirsty Lloyd-Jukes as an Entrepreneur in Residence to accelerate company creationPortfolio NewsTheolyticsTheolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investorPortfolio NewsSitryxSitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitisPortfolio NewsBeacon TherapeuticsAscend acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon Therapeutics for clinical and commercial AAV productionPortfolio NewsGenomicsGenomics plc and MassMutual's program enables more policyowners to understand health risks through innovative genetic testingPortfolio NewsOMass TherapeuticsOMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah TeichmannPortfolio NewsOxford NanoimagingRevolutionizing EV Research: Introducing ONI’s Next-Generation End-to-End SolutionPortfolio NewsTheolyticsMike Grey appointed Executive Chair of Theolytics’ Board of DirectorsPortfolio NewsPepGenPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyPortfolio NewsPepGenPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyPortfolio NewsOxford Quantum CircuitsPioneering Quantum Computing in the Energy Industry: Chevron Joins OQC's $100 Million RoundPortfolio NewsAmber TherapeuticsAmber Therapeutics announces positive preliminary results from its first-in-human investigation of Amber-UI, its new adaptive implanted pudendal neuromodulation system for urinary incontinencePortfolio NewsPepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1Portfolio NewsBeacon TherapeuticsBeacon Therapeutics Announces Positive 12-Month Data from Trial of Patients with X-Linked Retinitis PigmentosaPortfolio NewsPepGenPepGen Announces Pricing of $80.1 Million Underwritten Offering of Common StockPortfolio NewsQuantum Motion TechnologiesQuantum Motion wins bid to deliver first silicon quantum computing prototype to NQCCPortfolio NewsOrca ComputingORCA Computing to Deploy Quantum Photonics Testbed to UK National Quantum Computing CentrePortfolio NewsOxford IonicsOxford Ionics wins contract to deliver a quantum computer to the NQCCOSE NewsOSE's 2023 HighlightsPortfolio NewsGenomicsGenomics publishes results of NHS trial in European Journal of Preventative CardiologyPortfolio NewsOMass TherapeuticsCEO Ros Deegan appointed to UK Prime Minister's Business CouncilPortfolio NewsOrca ComputingORCA Computing Leaps Forward in Quantum Computing Race with AcquisitionPortfolio NewsMoA TechnologyMoa Reveals Data on Next-Generation Herbicides with New Modes of Action and Progress Towards Field TrialsPortfolio NewsPepGenMary Beth DeLena Joins PepGen as General Counsel and SecretaryPortfolio NewsCaristo DiagnosticsAgepha Pharma and Caristo Diagnostics Team Up to Fight Coronary InflammationPortfolio NewsUltromicsUltromics announces partnership to expedite development of Echo AI algorithmPortfolio NewsFluorokFluoRok awarded £750k grant by UKRI’s Faraday Battery ChallengePortfolio NewsGenomicsGenomics raises £35mn for advanced genetic testingPortfolio NewsPepGenPepGen Announces First Patient Dosed in Phase 2 Clinical Trial for Duchenne Muscular Dystrophy PatientsPortfolio NewsPepGenPepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)Portfolio NewsDiffBlueDiffblue Announces Citi as a Strategic InvestorPortfolio NewsScenic BiotechScenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882Portfolio NewsSpyBiotechSpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01Portfolio NewsEvolitoEvolito First in UK to Secure CAA Design Organisation Approval for Electric Propulsion SystemsPortfolio NewsTheolyticsTheolytics presents data at ESMO on its lead program being developed for Ovarian CancerPortfolio NewsOxford Quantum CircuitsOQC launches OQC Toshiko, the world’s first enterprise ready quantum platformOSE NewsOSE Response to Treasury's Independent Review of University SpinoutsPortfolio NewsBehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital TherapeuticsPortfolio NewsPepGenPepGen Announces Appointment of Howard Mayer, M.D. to Board of DirectorsPortfolio NewsOMass TherapeuticsOMass Therapeutics expands leadership team with the appointment of Melissa Faris as Chief Business OfficerPortfolio NewsOxford NanoimagingONI Welcomes Dr. Alex Aravanis, MD, PhD, as Newest Board MemberPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific OfficerPortfolio NewsCaristo DiagnosticsAmerican Heart Association Presentation found that AI technology used by Caristo can predict fatal and not-fatal cardiac eventsPortfolio NewsUltromicsCMS publishes final Clinical APC rule for Ultromics EchoGo® Heart FailurePortfolio NewsSitryxSitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseasesOSE NewsOxford Science Enterprises strengthens Health Tech team with appointments of two new Entrepreneurs in ResidencePortfolio NewsNeu.Health DigitalNeu Health Announces Key Appointments to its Board of DirectorsPortfolio NewsNeu.Health DigitalNeu Health is Revolutionizing Neurology Care with $3.6 Million in FundingPortfolio NewsBrill PowerBrill Power brings sustainable battery technology to 18th century Victorian mansion in UK firstPortfolio NewsPepGenPepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug ApplicationOSE NewsThe Oxford-Harrington Rare Disease Centre LaunchesPortfolio NewsRefeynRefeyn announces appointment of a new CEOPortfolio NewsCaristo DiagnosticsBritish Heart Foundation Features Breakthrough Heart Attack Prevention Technology in Online News Programme for World Heart DayPortfolio NewsSitryxSitryx raises additional $39 million to progress development of disease-modifying therapeuticsPortfolio NewsOMass TherapeuticsOMass Therapeutics Adds Mark Namchuk, PhD to Scientific Advisory BoardOxford ranked third most intensive science and innovation cluster in the worldPortfolio NewsNavenioNavenio Secures $6.3m to Boost Efficiency and Capacity for Patient Care Delivery TeamsPortfolio NewsNavLiveNavLive launches with a mission to revolutionise building projectsPortfolio NewsAlveogeneAlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory DisordersPortfolio NewsIota SciencesiotaSciences presents first encouraging data for use of new isoPick™ Single-Cell Picker for mass spectrometric analysis of single cellsPortfolio NewsOrbit DiscoveryOrano Med and Orbit Discovery enter Collaboration to discover novel targeted radioligand therapies for cancerPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Dr Russell Greig as Non-Executive Chair of the BoardPortfolio NewsPepGenPepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1Portfolio NewsIota SciencesiotaSciences and Quantum Design China Enter into Distribution AgreementPortfolio NewsAmber TherapeuticsAmber Tx acquires Bioinduction LimitedOSE NewsOxford Science Enterprises Appoints Ed Bussey as Chief Executive OfficerPortfolio NewsEvox TherapeuticsLandmark paper in Nature Communications highlights continued advances in Evox Therapeutics’s proprietary exosome engineering platformPortfolio NewsPepGenPepGen Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsPortfolio NewsEvox TherapeuticsEvox Therapeutics enters into agreement to advance next generation exosome-delivered AAV gene therapy for the treatment of heart diseasePortfolio NewsIota SciencesiotaSciences Appoints Dr. Michael Lutz as New Chief Executive OfficerPortfolio NewsUltromicsNew Technology Add-On Payment (NTAP) for Ultromics: Advancing HFpEF DiagnosisPortfolio NewsUltromicsStudy Confirms Ultromics’ AI Can Improve HFpEF Detection Using a Single Echocardiogram ViewPortfolio NewsProlificProlific announces £25m funding to improve AI systems with high quality, verifiable human insightsPortfolio NewsCaristo DiagnosticsCaristo Diagnostics Piloting New Cardiac Disease Diagnostic Technology in UK NHS HospitalsPortfolio NewsFluorokFluoRok launches with £3 million of funding to revolutionise the way fluorochemicals are producedPortfolio NewsCaristo DiagnosticsCaristo Diagnostics Applauds FDA Approval of Colchicine as First Anti-Inflammatory Drug for Cardiovascular DiseasePortfolio NewsBarinthus BiotherapeuticsVaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis BPortfolio NewsEvox TherapeuticsEvox Therapeutics Acquires Exosome AAV Technology and Intellectual PropertyPortfolio NewsBeacon TherapeuticsBeacon Therapeutics launches with £96 million to develop a new generation of gene therapies for retinal diseasesPortfolio NewsTheolyticsTheolytics presents data on THEO-260 and THEO-310 at ASCO and EHAPortfolio NewsMixergyEDP investment brings Mixergy to PortugalPortfolio NewsPQShieldPQShield partners with Tata Consultancy Services and eShardPortfolio NewsQuantum Motion TechnologiesSony Innovation Fund Joins Largest UK Quantum Investment in Second Close of Quantum Motion’s Funding RoundOSE NewsOxford University retains No. 1 spot for spinoutsPortfolio NewsOrca ComputingORCA Computing works with NVIDIA to implement hybrid quantum/classical algorithmsPortfolio NewsCovaticThe investment enables the privacy-first ad tech company to improve and scale its audience segmentation solution, A-TypePortfolio NewsNatcapnatcap releases new guide to the nature reporting landscapeOSE NewsPHTA and Oxford Science Enterprises join forces to support early stage startupsPortfolio NewsEvox TherapeuticsEvox Therapeutics granted key US exosome purification patentPortfolio NewsOMass TherapeuticsOMass Therapeutics Announces Appointment of New Board Chair and Series B ExtensionPortfolio NewsOxford FlowOxford Flow gas regulators approach 4 years of continuous, maintenance free operationPortfolio NewsUltromicsUltromics granted FDA Breakthrough Device DesignationOSE NewsOSE partners with top universities and investors for launch of USIT GuidePortfolio NewsOMass TherapeuticsOMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio ProgressPortfolio NewsBarinthus BiotherapeuticsVaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile in Women with HPVPortfolio NewsCaristo DiagnosticsCaristo Diagnostics Completes Series A Financing and Welcomes New CEOPortfolio NewsPQShieldPQShield collaborates with NCCoE to ease the real-world implementation of quantum-resistant cryptographyPortfolio NewsOrbit DiscoveryOrbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticalsPortfolio NewsGrey Wolf TherapeuticsGrey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid TumoursPortfolio NewsMixergyMixergy secures £9.2 million investment to expand their home energy and heat storage technologyPortfolio NewsSpyBiotechSpyBiotech Receives Grant from the Bill & Melinda Gates FoundationPortfolio NewsOxford FlowOxford Flow launch a new gas regulator size calculator and liquid regulator size calculatorPortfolio NewsOxford NanoimagingONI Appoints Paul Scagnetti as CEO to Implement Next Chapter of GrowthPortfolio NewsQuantum Motion TechnologiesQuantum Motion Raises £42 Million Investment RoundPortfolio NewsArchangel LightworksArchangel Lightworks secures £4 million seed round to build next generation lasercom technologyPortfolio NewsSpyBiotechSpybiotech appoints industry veteran Eddie Gray as Chair of its Board of DirectorsOSE NewsOur 2022 HighlightsOSE NewsOxford Science Enterprises strengthens Life Sciences investment team with appointment of Sanne de Jongh as PartnerPortfolio NewsIota SciencesiotaSciences launches new isoPick™ single-cell picker to further expand handling solutions for efficient cell biology & gene therapy applicationsPortfolio NewsOrbit DiscoveryOrbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeuticsPortfolio NewsScenic BiotechScenic Biotech enters cooperative research and development agreement with the National Institutes of Health for genetic modifier-based treatment approach for Niemann-Pick Type C DiseasePortfolio NewsBarinthus BiotherapeuticsVaccitech appoints industry veteran, Nadège Pelletier, Ph.D., as Chief Scientific OfficerPortfolio NewsGrey Wolf TherapeuticsGrey Wolf Therapeutics closes oversubscribed $49 million Series B financing to advance first-of-its-kind neoantigen creation approachesPortfolio NewsFirst Light FusionFirst Light Fusion to build demonstration facility at UKAEA’s Culham CampusPortfolio NewsAmber TherapeuticsAmber Therapeutics announces successful first-in-human implants of Amber-UI: an intelligent, closed-loop bioelectrical therapy for urge and mixed urinary incontinencePortfolio NewsScenic BiotechScenic Biotech strengthens drug discovery expertise in management team with the addition of Kristof Van EmelenPortfolio NewsOxford IonicsOxford Ionics announces £30m series A fundingPortfolio NewsPerspectumPerspectum completes $36 million first close of series C funding led by Oppenheimer HoldingPortfolio NewsArgonaut Therapeutics and Celleron Therapeutics announce completion of merger to form IngenOx TherapeuticsPortfolio NewsOrbit DiscoveryOrbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugsPortfolio NewsFirst Light FusionFirst Light Fusion congratulates the National Ignition Facility on its maiden gain resultOSE NewsOxfordVR to combine with BehaVR to confront the mental health crisis with the largest VR delivery platform for evidence-based digital therapeuticsPortfolio NewsFirst Light FusionFirst Light welcomes news of possible 'Net Energy Gain' success at The National Ignition FacilityPortfolio NewsPepGenPepGen announces IND-enabling preclinical data supporting progression of PGN-EDODM1 into clinical studiesPortfolio NewsUltromicsUltromics receives FDA clearance for its breakthrough device EchoGo Heart FailurePortfolio NewsNavenioBill Kloes joins Navenio as Chief Operating Officer to drive US expansionPortfolio NewsFirst Light FusionFirst Light Fusion targets 60 MW pilot plant to accelerate tritium productionPortfolio NewsBarinthus BiotherapeuticsVaccitech to host KOL webinar on the SNAPvax™ platform for inducing tolerance to treat celiac and other autoimmune diseasesPortfolio NewsOrca ComputingORCA Computing hires Per Nyberg as Chief Commercial OfficerPortfolio NewsPepGenPepGen announces positive preclinical data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, three novel duchenne muscular dystrophy candidatesPortfolio NewsBarinthus BiotherapeuticsVaccitech reports third quarter 2022 financial results and recent corporate developmentsPortfolio NewsOMass TherapeuticsPublication in Nature Chemistry between Omass Therapeutics and co-founder Dame Carol Robinson demonstrates the benefits of native mass spectrometry in the interrogation of target ecosystems and drug discoveryPortfolio NewsPepGenPepGen reports third quarter 2022 financial results and recent corporate developmentsPortfolio NewsGenomicsGenomics announces successful world-first pilot using improved genomic risk assessment in cardiovascular disease prevention in the NHSPortfolio NewsOsler DiagnosticsOsler Diagnostics raises $85 million in Series C financingPortfolio NewsUtil closes $6 million seed investment round led by EldridgePortfolio NewsEvolitoEvolito appoints Chris Harris as Chief Executive OfficerPortfolio NewsQuantum Motion TechnologiesQuantum Motion industry milestone brings mass production of quantum chips closerPortfolio NewsScenic BiotechScenic Biotech appoints Jens Würthner as Chief Medical OfficerOSE NewsDJS AntibodiesDJS Antibodies to be acquired by AbbViePortfolio NewsDJS AntibodiesAbbVie acquires DJS Antibodies, further strengthening immunology pipelinePortfolio NewsNucleome TherapeuticsNucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicinesPortfolio NewsPepGenPepGen presents data from its Duchenne Muscular Dystrophy program at World Muscle Society CongressPortfolio NewsOxford FlowOxford Flow and KOSO Kent Introl announce global partnershipOSE NewsOxford University named world's top university for the 7th consecutive yearPortfolio NewsGenomicsGenomics announces genetic risk scoring partnership with Our Future Health to test new personalised disease prevention approachesPortfolio NewsTheolyticsTheolytics presents CAF-targeting therapy for stromal rich tumours and strengthens leadership teamPortfolio NewsUltromicsUltromics joins FNIH partnership to transform heart failure detectionPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits partners with Cyxtera to improve accessibility to quantum computersPortfolio NewsPepGenPepGen reports positive data from Phase 1 trial of PGN-ED051 for the treatment of Duchenne Muscular DystrophyPortfolio NewsFirst Light FusionGovernment Chief Scientific Adviser visits UK Atomic Energy Authority and First Light FusionPortfolio NewsPepGenPepGen appoints Habib Dable to Board of DirectorsPortfolio NewsOdqaOdqa Renewable Energy Technologies emerges as frontrunner in the solar thermal industry with proprietary receiver technologyPortfolio NewsOpsydia secures investment to drive growth in its innovative security solutions for the diamond sectorPortfolio NewsGenomicsGenomics announces that Simon Dingemans has joined its board as the new chairPortfolio NewsRefeynRefeyn appoints Jean-Paul Mangeolle as new Non-Executive DirectorPortfolio NewsPepGenPepGen reports second quarter 2022 financial results and recent corporate developmentsPortfolio NewsBarinthus BiotherapeuticsVaccitech reports second quarter 2022 financial results and recent corporate developmentsPortfolio NewsMiroBioGilead Sciences to acquire MiroBioOSE NewsMiroBioMiroBio to be acquired by Gilead Sciences for approximately $405 millionPortfolio NewsPepGenPepGen appoints Caroline Godfrey, Ph.D. to the company's scientific advisory boardPortfolio NewsFirst Light FusionFirst Light Fusion strikes long-term collaboration agreement with engineering leaders IDOMPortfolio NewsBrill PowerBrill powering its way to make batteries smarter with $10.5m Series A roundOSE NewsOxford Science Enterprises raises £250 millionPortfolio NewsOMass TherapeuticsOMass Therapeutics appoints Dr Jon Roffey as Vice President, Head of Medicinal ChemistryPortfolio NewsSpyBiotechSpyBiotech appoints seasoned biotech executive Mark Leuchtenberger as Chief Executive OfficerPortfolio NewsOxford IonicsOxford Ionics and Infineon join forces to develop leading trapped ion quantum processorsPortfolio NewsEvolitoEvolito acquires ElectroflightPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits raises £38 million Series A to accelerate R&D and expand into Asia-PacificPortfolio NewsPQShieldPQShield algorithms to be standardised as the National Institute of Standards and Technology (NIST) announces the first international Post-Quantum Cryptography standardsPortfolio NewsMiroBioMiroBio raises $97 million Series B financing to develop checkpoint agonists for treatment of autoimmune diseasesPortfolio NewsBarinthus BiotherapeuticsVaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1Portfolio NewsPepGenPepGen reports first quarter 2022 financial results and recent corporate developmentsPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Dina Anderson as Vice President of OperationsPortfolio NewsOrca ComputingOrca Computing provides UK MoD with first quantum computerPortfolio NewsBibliuEdTech leader BibliU raises $15 million in Series B fundingPortfolio NewsOrca ComputingOrca Computing completes $15 million Series A funding roundPortfolio NewsBarinthus BiotherapeuticsArbutus and Vaccitech dose first patient in Phase 2a clinical trial combining therapies for the treatment of chronic hepatitis B virusPortfolio NewsTheolyticsTheolytics' £1m project with Innovate UK to develop a novel therapy for multiple myeloma patientsPortfolio NewsMoA TechnologyMoA Technology raises $44 million in Series B financing to progress novel herbicide pipelinePortfolio NewsPerspectumFDA grants clearance to Perspectum's CoverScan - A new platform-based tool to assess multiple organs in one MRI scanPortfolio NewsSalience LabsSalience Labs raises $11.5 million seed to develop ultra high-speed chips using photonics for AI applicationsPortfolio NewsOxford FlowOxford Flow’s ES valve wins prestigious engineering award at (OTC) Offshore Technology ConferencePortfolio NewsPepGenPepGen announces pricing of initial public offeringPortfolio NewsSpyBiotechStudies using SpyBiotech’s vaccine technology shows potential against Covid-19 and other coronavirusesPortfolio NewsOMass TherapeuticsOMass Therapeutics raises $100 million in Series B financing to progress drug pipeline in immunology and rare diseasesPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Phil Boyd as Chief Financial OfficerOSE NewsOxford Science Enterprises appoints Richard Laxer, former Chairman and CEO of GE Capital, as a Non-Executive DirectorPortfolio NewsUtil announces the closing of a seed roundPortfolio NewsRefeynRefeyn closes Series B funding roundPortfolio NewsOxfordVR technology a world-first success in automating psychological therapy using virtual realityPortfolio NewsBarinthus BiotherapeuticsVaccitech announces notification of milestone and royalty revenue relating to sales of VaxzevriaPortfolio NewsOMass TherapeuticsPublication in Nature by OMass Founder, Professor Dame Carol Robinson, shows power of native mass spectrometry in drug discoveryPortfolio NewsPepGenPepGen announces first participant dosed in a Phase 1 clinical trial of PGN-EDO51 for the treatment of Duchenne Muscular DystrophyPortfolio NewsFirst Light FusionFirst Light Fusion achieves world first fusion result, proving unique new target technologyPortfolio NewsPepGenPepGen appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical DevelopmentOSE NewsNew report highlights Oxford as the UK’s leading University for spinout creation with Oxford Science Enterprises named as most active fund focused solely on a single institutionOSE NewsOxford Science Enterprises strengthens investment teams with two new appointmentsPortfolio NewsPepGenPepGen continues to build leadership team with additions of Senior Vice President, Clinical Operations and Vice President, ToxicologyPortfolio NewsScenic BiotechScenic Biotech and the Barth Syndrome Foundation announce partnership to explore genetic modifiers to find tailored treatment for complex rare diseasePortfolio NewsBarinthus BiotherapeuticsVaccitech reports full-year 2021 financial results and recent corporate developmentsPortfolio NewsBibliuHigher education tech leader BibliU announces learning enablement platformPortfolio NewsMixergyMixergy partners with UK’s largest online plumbing and heating merchant to offer full range of tanks nationwidePortfolio NewsOsler DiagnosticsOsler Diagnostics publishes update on its breakthrough product, the Osler OriginPortfolio NewsOsler DiagnosticsOsler Diagnostics appoints Chris Smith as Chairman of the Board and David Berry as a Non-Executive DirectorPortfolio NewsMind FoundryMind Foundry win CogX Explainable AI Award for 2022Portfolio NewsPepGenPepGen announces approval by Health Canada of CTA to begin first in human trials of PGN-EDO51 to treat Duchenne Muscular DystrophyOSE NewsOxford Science Enterprises enters agreement with Lothbury to develop state-of-the-art R&D facilities in Oxford City CentrePortfolio NewsScenic BiotechScenic Biotech announces $31 million financing to progress pipeline of genetic modifiers in cancer and rare diseasesPortfolio NewsMiroBioMiroBio continues expansion of executive leadership team with key appointments to advance development of checkpoint agonist antibodies for autoimmune diseasePortfolio NewsOMass TherapeuticsOMass Therapeutics establishes scientific advisory board of leading expertsPortfolio NewsOrbit DiscoveryOrbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologiesPortfolio NewsOMass TherapeuticsOmass Therapeutics OdyssION™ drug discovery platform makes progress in drugging the undruggablePortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits becomes first european quantum company on Amazon BraketPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Nigel Clark as Chief Business OfficerPortfolio NewsUltromicsUltromics: Wolverhampton NHS cardiologists to use new cloud technology to interpret echocardiogramsPortfolio NewsFirst Light FusionFirst Light Fusion announces close of Series C fund raisePortfolio NewsNucleome TherapeuticsNucleome Therapeutics announces formation of advisory boardOSE NewsOxford Science Enterprises strengthens investment teams with two senior appointmentsPortfolio NewsMetaboards announces Executive Chairman appointmentPortfolio NewsRefeynRefeyn announces the launch of its new TwoMP Auto mass photometerPortfolio NewsOpsydia introduces Surface ID System to complement existing sub-surface technologyPortfolio NewsQuantum Motion TechnologiesQuantum Motion opens new lab in London to build scalable quantum computerPortfolio NewsPerspectumPerspectum announces first patient recruited for multi-year collaborative primary sclerosing cholangitis (PSC) pediatric studyPortfolio NewsPQShieldPQShield raises $20 million in Series A funding to fuel global growthOSE NewsOxford Science Enterprises enters 2022 with strengthened senior leadership teamPortfolio NewsBrill PowerBrill Power announces Harwell Campus to provide testbed demonstrating energy storage innovationsPortfolio NewsOxford NanoimagingOxford Nanoimaging closes $75 million Series B led by ARCH Venture Partners and Casdin CapitalPortfolio NewsBarinthus BiotherapeuticsVaccitech announces Cancer Research UK dose first patient in Phase I/IIa trial of lung cancer immunotherapy vaccinePortfolio NewsNavenioNavenio secures $12.6 million investment to accelerate global growth in healthcare and beyondOSE NewsOxford Science Enterprises Board updatePortfolio NewsUltromicsUltromics breakthrough study shows AI is a capable of independently reading stress echocardiogramsPortfolio NewsAlethiomicsAlethiomics launches to advance its multi-omics target discovery pipeline in blood cancerPortfolio NewsCircadian TherapeuticsCircadian Therapeutics announces the first subject recruited to Phase I study for CT-1500, marking move to a clinical stage companyPortfolio NewsBarinthus BiotherapeuticsVaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccinesPortfolio NewsBarinthus BiotherapeuticsVaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBVPortfolio NewsOxford Semantic TechnologiesDow Jones enhances product line with semantic innovation from Oxford Semantic TechnologiesPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits coming to Amazon Braket - bringing quantum to EuropePortfolio NewsMeltwater acquires AI spin-out from Oxford University’s Department of Computer Science to help build one of the largest knowledge graphs of public informationPortfolio NewsMixergyEcobubl: A new Mixergy stockist and training centrePortfolio NewsSpyBiotechSpyBiotech announces the appointment of Simon Jones as VP, Finance and Operations and expansion of the scientific teamPortfolio NewsBarinthus BiotherapeuticsVaccitech reports third quarter 2021 financial results and recent corporate developmentsPortfolio NewsBarinthus BiotherapeuticsVaccitech’s VTP-300 was well-tolerated and induced T cells against all targeted HBV antigens in both healthy volunteers and patients with chronic HBV infection in interim analysesPortfolio NewsUltromicsCaption Health and Ultromics partner to put heart disease detection and management tools in more handsPortfolio NewsCaristo DiagnosticsCaristo Diagnostics announces CT coronary perivascular fat assessment can stratify cardiac risk associated with high-risk plaquesPortfolio NewsEvox TherapeuticsEvox Therapeutics expands its exosome patent portfolioPortfolio NewsPepGenPepGen bolsters R&D team with appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical DevelopmentPortfolio NewsNavenioNavenio and HERE Technologies to bring increased efficiency to indoor location & mapping with global partnershipPortfolio NewsNucleome TherapeuticsGene linked to doubling the risk of death due to COVID-19 identified using technology exclusively licensed to Nucleome TherapeuticsPortfolio NewsOMass TherapeuticsOMass Therapeutics unveils rich drug discovery pipeline targeting intractable or inadequately drugged membrane and complex-bound proteinsPortfolio NewsBarinthus BiotherapeuticsVaccitech announces publication of second Phase 1 clinical trial results of ChAdOx1 vaccine in development for the MERS coronavirusPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits collaborates with the National Quantum Computing Centre to boost UK quantum capabilityPortfolio NewsBibliuWichita State University Campus of Applied Sciences and Technology adopts BibliU Universal LearningPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits pledges carbon neutrality by 2022Portfolio NewsPepGenPepGen appoints Noel Donnelly as Chief Financial OfficerPortfolio NewsEvox TherapeuticsLandmark paper highlights Evox Therapeutics’ cutting edge exosome engineering approach for enhanced surface display of biologicsPortfolio NewsFirst Light FusionFirst Light Fusion represents UK fusion sector at the UK Government’s Global Investment SummitPortfolio NewsBrill PowerBrill Power launches the first in a new class of 'intelligent' battery management systems set to revolutionise battery performancePortfolio NewsUltromicsUltromics announces collaboration with Janssen to develop AI for patients with amyloidosis with cardiac involvementPortfolio NewsOpsydia technology advances to secure identity of melee diamondsPortfolio NewsPQShieldPQShield announces new hires to accelerate business growthPortfolio NewsEvolitoYASA spin-out Evolito to electrify aerospace market with ultra-high performance, low-weight electric motorsPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits appoints Peter George as Chairperson of its BoardPortfolio NewsPepGenPepGen announces new additions to leadership team and Board of DirectorsOSE NewsOxford University retains top spot in world rankings for 6th consecutive yearPortfolio NewsGenomicsGenomics academic founder and CEO, Sir Peter Donnelly, awarded Royal Society Gabor medalPortfolio NewsUltromicsUltromics raises $33 million in Series B funding to help transform cardiac disease treatmentPortfolio NewsPepGenPepGen announces closing of $112.5 million crossover financing to advance transformative therapies for neuromuscular diseasesPortfolio NewsCircadian TherapeuticsCircadian Therapeutics and Arquimea sign a collaboration agreement for the development of a molecule (AP-2) for the treatment of diseases affecting the nervous systemPortfolio NewsYASAElectric motor technology company YASA acquired by Mercedes-BenzPortfolio NewsOrbit DiscoveryOrbit Discovery announces $7.6 million funding to accelerate growth in peptide discovery businessPortfolio NewsPerspectumPerspectum launches new clinical study to investigate integrated diagnostics to enable precision medicine for liver cancer patientsPortfolio NewsTheolyticsTheolytics expands Series A financing and welcomes M Ventures as a new investorPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits delivers the UK’s first Quantum Computing as-a-ServicePortfolio NewsBarinthus BiotherapeuticsArbutus Biopharma and Vaccitech announce clinical trial collaboration for chronic hepatitis B virus infectionPortfolio NewsUltromicsUltromics: EchoGo predicts cardiac-related COVID-19 mortality revealed in WASE studyPortfolio NewsFirst Light FusionUK Science Minister Amanda Solloway MP to launch First Light Fusion’s maiden ‘Big Gun’ fusion campaignPortfolio NewsBrill PowerDNV verifies Brill Power’s new battery management system technologyPortfolio NewsOxford NanoimagingOxford Nanoimaging among the +20 organisations brought together by the Cell and Gene Therapy Catapult to accelerate technology development in cell and gene therapy manufacturingPortfolio NewsPepGenPepGen strengthens leadership team with SVP of Chemistry, Manufacturing & Controls and VP of Finance AppointmentsPortfolio NewsNucleome TherapeuticsNucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its BoardPortfolio NewsNucleome TherapeuticsNucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal NaturePortfolio NewsOxford NanoimagingOxford Nanoimaging welcomes Dr Tyler Ralston as Chief Technology OfficerPortfolio NewsFirst Light FusionFirst Light Fusion installs UK’s biggest two-stage hyper-velocity gas gunPortfolio NewsPerspectumPerspectum partners in a new study in Singapore for the early detection of liver cancer using precision medicinePortfolio NewsBarinthus BiotherapeuticsVaccitech announces closing of $110.5 million initial public offeringPortfolio NewsBarinthus BiotherapeuticsVaccitech announces pricing of initial public offeringPortfolio NewsMoA TechnologyMoA Technology raises a further £5 million in Series A financing bringing the total round to £12mPortfolio NewsPerspectumPerspectum study shows measurable organ impairment in long COVID patientsPortfolio NewsUltromicsUltromics CE mark's EchoGo CorePortfolio NewsOxford EndovascularOxford Endovascular raises $10 million to develop its origami engineered medical device to prevent brain haemorrhagePortfolio NewsQuantum Motion TechnologiesQuantum Motion computing breakthrough shows blueprint for scalable futurePortfolio NewsCaristo DiagnosticsCaristo Diagnostics announces EU approval for AI technology which can predict heart attacks years in advancePortfolio NewsPerspectumPerspectum research links high liver fat to increased risk of hospitalization in COVID-19 patients with obesityPortfolio NewsBarinthus BiotherapeuticsVaccitech appoints Joseph Scheeren, PharmD, to its Board of DirectorsPortfolio NewsBarinthus BiotherapeuticsVaccitech doses first patient in HPV001, a Phase 1/2 clinical trial of VTP-200 immunotherapeutic for high-risk persistent HPV infectionPortfolio NewsBarinthus BiotherapeuticsVaccitech completes $168 million Series B financing to advance three clinical programs through Phase 2 resultsPortfolio NewsSpyBiotechSpyBiotech announces the appointments of Dan Menichella as Non-Executive Director and Dr Norman Begg as Scientific AdvisorPortfolio NewsMoA TechnologyMoA Technology appoints Virginia Corless as Chief Executive OfficerPortfolio NewsBarinthus BiotherapeuticsVaccitech appoints two independent board directorsPortfolio NewsGenomicsGenomics completes oversubscribed $30m funding roundPortfolio NewsPerspectumPerspectum lands top spot in Alantra Pharma Fast 50 rankingsPortfolio NewsPepGenPepGen announces formation of scientific advisory boardPortfolio NewsT-Cypher BioT-Cypher Bio separates from Orbit Discovery to build a pipeline of TCR therapeutics for solid tumours and other indicationsPortfolio NewsEvox TherapeuticsEvox Therapeutics completes £69.2 million Series C financingPortfolio NewsBrill Power£2.5 million for intelligent battery technology start-up, Brill PowerPortfolio NewsMixergyMixergy tanks now included at CALA Homes developmentPortfolio NewsSpyBiotechSpyBiotech raises $32.5 million in Series A funding and appoints Lutz B. Giebel as ChairmanPortfolio NewsFirst Light FusionProfessor Jerry Chittenden joins First Light Fusion’s Advisory BoardPortfolio NewsPepGenPepGen appoints James McArthur, Ph.D., as President and Chief Executive OfficerPortfolio NewsScenic BiotechScenic Biotech appoints Dr. Philippe Dro as Independent ChairmanPortfolio NewsBarinthus BiotherapeuticsVaccitech doses first patient in HBV002, a Phase 1b/2a clinical trial of VTP-300 immunotherapeutic candidate for chronic HBV patientsPortfolio NewsEvox TherapeuticsJohn McHutchison joins the board of Evox TherapeuticsPortfolio NewsPerspectumPerspectum’s CoverScan MD approved by the UK’s MHRA – the world’s first integrated imaging service capable of mapping the impact of COVID-19 on the bodyPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits lab takes delivery of first Proteox worldwidePortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits state-of-the-art quantum laboratory opensPortfolio NewsOxford FlowEx-Centrica and BP boss Iain Conn joins the board of Oxford FlowPortfolio NewsUltromicsUltromics receives FDA clearance for EchoGo Pro; a first-of-kind solution to help diagnose CADPortfolio NewsTheolyticsTheolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapiesPortfolio NewsPerspectumPerspectum issued CPT Codes for LiverMultiScan by the American Medical Association to help clinicians diagnose and treat liver diseasePortfolio NewsHEXRHEXR launches smartphone fitting app: Bespoke, 3D printed helmets now accessible to millionsPortfolio NewsPepGenPepGen raises $45M in Series A funding, led by RA CapitalPortfolio NewsCounterfeit drugs and illegitimate vaccines, could be a thing of the past with new breakthrough testing technology from Proxisense and Oxford UniversityPortfolio NewsRefeynRefeyn closes Series A funding round, led by Northpond VenturesOSE NewsBarinthus BiotherapeuticsBreakthrough for Oxford's covid vaccine, co-invented by VaccitechPortfolio NewsEvox TherapeuticsEvox Therapeutics announces launch of strategic collaboration with the University of OxfordPortfolio NewsMind FoundryMind Foundry raises an additional $13.6 million in Series A fundingOSE NewsBase GenomicsOxford Science Enterprises announces the sale of Base Genomics to Exact SciencesPortfolio NewsBarinthus BiotherapeuticsVaccitech expands management team with new hires, including CMO and CFOOSE NewsOxford Science Enterprises appoints Alexis Dormandy as Chief Executive OfficerPortfolio NewsFirst Light FusionFirst Light Fusion: Fusion energy can be the most cost competitive source of baseload power, at the same level as renewablesPortfolio NewsScenic BiotechScenic Biotech enters into genetic modifier collaboration with GenentechPortfolio NewsBarinthus BiotherapeuticsVaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate